Elotuzumab -- Effects, Usage and Side Effects
Elotuzumab is a monoclonal antibody used to treat multiple myeloma. It works by activating the immune system to target and destroy cancer cells, always used in combination therapy.
Things worth knowing about "Elotuzumab"
Elotuzumab is a monoclonal antibody used to treat multiple myeloma. It works by activating the immune system to target and destroy cancer cells, always used in combination therapy.
What is Elotuzumab?
Elotuzumab is a humanized monoclonal antibody approved for the treatment of multiple myeloma, a cancer of plasma cells in the bone marrow. Marketed under the brand name Empliciti, it has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Elotuzumab is not used as a standalone treatment; it is always administered in combination with other anticancer agents.
Mechanism of Action
Elotuzumab specifically targets the cell surface protein SLAMF7 (also known as CS1, CRACC, or CD319), which is highly expressed on myeloma cells but is present at very low levels on most normal tissues. Its therapeutic effect is achieved through two main pathways:
- Direct NK cell activation: Since natural killer (NK) cells also express SLAMF7, elotuzumab binds to and activates these immune cells, enhancing their ability to kill tumor cells.
- Antibody-dependent cellular cytotoxicity (ADCC): By binding to SLAMF7 on myeloma cells, elotuzumab flags them for destruction by immune effector cells.
This dual mechanism makes elotuzumab a true immunotherapeutic agent that harnesses the body's own immune defenses to fight the cancer.
Indications and Usage
Elotuzumab is approved for adult patients with relapsed or refractory multiple myeloma (i.e., after disease recurrence or failure of prior therapy). It is used in two approved combination regimens:
- Elotuzumab + Lenalidomide + Dexamethasone (ELd): For patients who have received at least one prior therapy.
- Elotuzumab + Pomalidomide + Dexamethasone (EPd): For patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
Elotuzumab is administered as an intravenous infusion according to a defined treatment cycle that varies depending on the combination used. The standard dose is 10 mg/kg body weight.
Side Effects
As with all cancer medications, elotuzumab may cause side effects. Commonly reported adverse effects include:
- Infusion-related reactions (e.g., fever, chills, blood pressure changes) -- often manageable with premedication
- Fatigue and weakness
- Diarrhea and nausea
- Increased susceptibility to infections due to immune suppression
- Cough and respiratory tract infections
- Changes in blood counts (e.g., leukopenia, lymphopenia)
Before each infusion, premedication with dexamethasone, H1 and H2 antihistamines, and acetaminophen is recommended to reduce the risk of infusion reactions.
Clinical Evidence
The efficacy of elotuzumab has been demonstrated in several Phase III clinical trials:
- ELOQUENT-2 trial: Showed a significant improvement in progression-free survival for ELd versus lenalidomide and dexamethasone alone in patients with relapsed or refractory multiple myeloma.
- ELOQUENT-3 trial: Demonstrated the superiority of EPd over pomalidomide and dexamethasone alone in heavily pretreated patients.
References
- Lonial S et al. - Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2015; 373(7): 621-631.
- European Medicines Agency (EMA) - Empliciti (Elotuzumab): Summary of Product Characteristics. EMA, 2016. Available at: https://www.ema.europa.eu
- Dimopoulos MA et al. - Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2018; 379(19): 1811-1822.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryImpact Training
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Elotuzumab